Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.